Abstract
Cancer stem cells (CSCs) are considered to be the origin of cancer and it is suggested that they are resistant to chemotherapy. Current therapies fail to eradicate CSCs and therefore selecting a resistant cell subset that is able to facilitate tumor recurrences. Betulinic acid (BetA) is a broad acting natural compound, shown to induce cell death via the inhibition of the stearoyl-CoA- desaturase (SCD- 1). This enzyme converts saturated fatty acids into unsaturated fatty acids and is over-expressed in tumor cells. Here we show that BetA induces rapid cell death in all colon CSCs tested and is able to affect the CSCs directly as shown, via the loss of clonogenic capacity. Similar results were observed with inhibition of SCD-1, suggesting that SCD-1 activity is indeed a vulnerable link in colon CSCs and can be considered an ideal target for therapy in colon cancer.
Keywords: Betulinic acid, cancer stem cells, cancer treatment, colon cancer, stearoyl CoA-desaturase, tumor resistance.
Current Stem Cell Research & Therapy
Title:Betulinic Acid Kills Colon Cancer Stem Cells
Volume: 11 Issue: 5
Author(s): Lisette Potze, Simone di Franco, Jan H. Kessler, Giorgio Stassi and Jan Paul Medema
Affiliation:
Keywords: Betulinic acid, cancer stem cells, cancer treatment, colon cancer, stearoyl CoA-desaturase, tumor resistance.
Abstract: Cancer stem cells (CSCs) are considered to be the origin of cancer and it is suggested that they are resistant to chemotherapy. Current therapies fail to eradicate CSCs and therefore selecting a resistant cell subset that is able to facilitate tumor recurrences. Betulinic acid (BetA) is a broad acting natural compound, shown to induce cell death via the inhibition of the stearoyl-CoA- desaturase (SCD- 1). This enzyme converts saturated fatty acids into unsaturated fatty acids and is over-expressed in tumor cells. Here we show that BetA induces rapid cell death in all colon CSCs tested and is able to affect the CSCs directly as shown, via the loss of clonogenic capacity. Similar results were observed with inhibition of SCD-1, suggesting that SCD-1 activity is indeed a vulnerable link in colon CSCs and can be considered an ideal target for therapy in colon cancer.
Export Options
About this article
Cite this article as:
Potze Lisette, di Franco Simone, H. Kessler Jan, Stassi Giorgio and Paul Medema Jan, Betulinic Acid Kills Colon Cancer Stem Cells, Current Stem Cell Research & Therapy 2016; 11 (5) . https://dx.doi.org/10.2174/1574888X11666151203223512
DOI https://dx.doi.org/10.2174/1574888X11666151203223512 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Virally Targeted Therapies of EBV-Associated Tumors
Current Cancer Drug Targets Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Feature Classification and Analysis of Lung Cancer Related Genes through Gene Ontology and KEGG Pathways
Current Bioinformatics Protein Structural Analysis of Calbindin D<sub>28k</sub> Function and Dysregulation: Potential Competition Between Ca<sup>2+</sup> and Zn<sup>2+</sup>
Current Alzheimer Research Alginate Based Nanocarriers for Drug Delivery Applications
Current Pharmaceutical Design Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Current Cancer Therapy Reviews Evolutionary Significance of Iodine
Current Chemical Biology HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
Current Cancer Drug Targets Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Serum Interleukin Levels and Insulin Resistance in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Nutritional Support in Cancer
Current Nutrition & Food Science Withdrawal Notice: Role of MicroRNAs (224 and 96) as Novel Biomarkers for Hepatocellular Carcinoma
Current Cancer Therapy Reviews miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Current Cancer Drug Targets Oral Nano-Delivery Systems for Colon Targeting Therapy
Pharmaceutical Nanotechnology Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents